3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Colorectal Neoplasms
5
Colonic Neoplasms
5
Rectal Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Cisplatin
116
Radiotherapy
84
Paclitaxel
77
Fluorouracil
62
Carboplatin
41
Drug Therapy
38
pembrolizumab
33
Irinotecan
33
tislelizumab
27
Docetaxel
26
Neoadjuvant Therapy
24
Oxaliplatin
23
toripalimab
22
sintilimab
19
camrelizumab
19
Radiation
19
Esophagectomy
18
Capecitabine
17
130-nm albumin-bound paclitaxel
17
Surgical Procedures, Operative
16
Nivolumab
16
Leucovorin
15
Cetuximab
14
TP protocol
12
S 1 (combination)
12
Radiotherapy, Intensity-Modulated
12
Albumin-Bound Paclitaxel
12
nimotuzumab
11
apatinib
10
Immune Checkpoint Inhibitors
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
In Situ Hybridization, Fluorescence
×
Gastrointestinal
×
Clear all
NCT00900094
2012-02-07
IRB 2000-294
University of Michigan Rogel Cancer Center
Completed
200 enrolled